Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients
Status:
Withdrawn
Trial end date:
2029-04-01
Target enrollment:
Participant gender:
Summary
To investigate the feasibility of delivering oral azacitidine (CC-486) as a consolidation
regimen from the time of first complete remission (CR1), in patients with acute myelogenous
leukemia (AML) eligible for curative intent Allogeneic Stem Cell Transplant (ASCT).
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Collaborators:
Bristol-Myers Squibb National Cancer Institute (NCI)